{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-050055","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.306612+00:00","generated_at":"2026-05-20T03:17:35.715700+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CERo Therapeutics enters new employment agreements with CEO and CFO effective June 4, 2025","bullets":["CEO Chris Ehrlich receives base salary of $480,000/year and a one-time performance bonus of 50% of base salary.","CFO Andrew Kucharchuk receives base salary of $300,000/year and a one-time performance bonus of 30% of base salary.","Ehrlich receives equity awards including an option for 238,971 shares (granted March 4, 2025) and a second option for 185,529 shares.","Kucharchuk receives an option for 152,500 shares, subject to board approval, vesting over time and performance milestones.","The new agreements replace prior consulting agreements and convert both roles to full-time employment."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-050055","json":"https://secwatch.observer/filing/0001213900-25-050055.json","markdown":"https://secwatch.observer/filing/0001213900-25-050055.md","text":"https://secwatch.observer/filing/0001213900-25-050055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/0001213900-25-050055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/ea0244195-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-20T03:17:35.715700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03bb5afadd","claim":"Chris Ehrlich was appointed as Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"the Company agreed to employ Mr. Ehrlich as the Company’s Chief Executive Officer as of and from June 4, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/0001213900-25-050055-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"739bae153d","claim":"Andrew Albert Kucharchuk was appointed as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"the Company agreed to employ Mr. Kucharchuk as the Company’s Chief Financial Officer as of and from June 4, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/0001213900-25-050055-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}